Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China

Abstract The combination of venetoclax (VEN) and azacitidine (AZA) has transformed the treatment of acute myeloid leukemia (AML) in patients ineligible for intensive therapy. Nevertheless, real-world evidence on long-term outcomes in patients with AML treated with VEN + AZA remains limited. A retros...

Cijeli opis

Bibliografski detalji

Glavni autori:	Xuexing Chen, Qiong Yan, Chunfang Li, Fei Liu, Shaojun Guo, Juan Zhao, Yan Liang, Haiyan Wang, Weiming Li, Guolin Yuan
Format:	Artigo
Jezik:	Inglês
Izdano:	Nature Portfolio 2026-04-01
Serija:	Scientific Reports
Teme:	Venetoclax Acute myeloid leukemia Long-term treatment Efficacy Prognostic factors
Online pristup:	https://doi.org/10.1038/s41598-026-50426-0
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!